MyBioSource

Last updated
MyBioSource
Company typePublic
Industry Biotech, Life Sciences, Manufacturing
Founded2007 (2007) in Vancouver, Canada
Headquarters,
United States
Area served
Worldwide
Number of employees
25–30
Website www.mybiosource.com

MyBioSource, Inc. is a biotechnological products distribution company formed to create a large portfolio of laboratory research reagents, both hard to find and common items, with worldwide distributions. Backed by a network of laboratories and manufacturers, the company was launched in 2007 in Vancouver, British Columbia, Canada. Headquarters and operations were relocated to San Diego, United States.

Contents

Products

The company distributes a number of science reagents and assay kits, including custom recombinant proteins and antibodies, real time PCR and quantitative ELISA kits. The company's current catalog lists over 1 million individual products used in academic, biotechnological, and pharmaceutical industries.

Peer reviews

One peer-reviewed article that compared the specificity of several, commercially available kits for glucagon and oxyntomodulin found that the MyBioSource assay (MBS701592) for detecting oxyntomodulin "yielded inconsistent results". And another article [1] investigated the specificity of commercially available EIA kits for identification of neutralizing antibodies to adenovirus Ad36 found that "all seronegative samples (as determined by SNA) were false positive" by MyBioSource's Ad36 EIA (MBS705802).

Publications with MyBioSource products

See also

References

  1. Dubuisson, Olga (January–February 2015). "Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans" . Journal of Diabetes and Its Complications. 29 (1): 83–87. doi:10.1016/j.jdiacomp.2014.09.004. PMID   25312598 . Retrieved December 9, 2021.
  2. Dubuisson, Olga (January–February 2015). "Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans" . Journal of Diabetes and Its Complications. 29 (1): 83–87. doi:10.1016/j.jdiacomp.2014.09.004. PMID   25312598 . Retrieved December 9, 2021.